FAAP20

Summary

FAAP20 (FA core complex associated protein 20, HGNC:26428) is a protein-coding gene on chromosome 1p36.33, encoding Fanconi anemia core complex-associated protein 20 (Q6NZ36). Component of the Fanconi anemia (FA) complex required to recruit the FA complex to DNA interstrand cross-links (ICLs) and promote ICLs repair. It is a selective cancer dependency (DepMap: 12.4% of cell lines).

Enables K63-linked polyubiquitin modification-dependent protein binding activity and ubiquitin-modified protein reader activity. Involved in interstrand cross-link repair and translesion synthesis. Located in cell junction; chromatin; and nuclear body. Part of Fanconi anaemia nuclear complex.

Source: NCBI Gene 199990 — RefSeq curated summary.

At a glance

• GWAS associations: 92
• Clinical variants (ClinVar): 43 total — 2 pathogenic
• Cancer dependency (DepMap): dependent in 12.4% of screened cell lines
• MANE Select transcript: NM_182533

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26428
Approved symbol	FAAP20
Name	FA core complex associated protein 20
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ31031
Ensembl gene	ENSG00000162585
Ensembl biotype	protein_coding
OMIM	615183
Entrez	199990

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 9 protein_coding, 4 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 3 retained_intron

ENST00000378543, ENST00000378546, ENST00000400918, ENST00000400919, ENST00000401813, ENST00000414253, ENST00000420515, ENST00000420964, ENST00000428120, ENST00000440825, ENST00000469733, ENST00000476803, ENST00000487186, ENST00000497675, ENST00000514625, ENST00000904918, ENST00000904919, ENST00000904920, ENST00000925510

RefSeq mRNA: 9 — MANE Select: NM_182533 NM_001146310, NM_001256945, NM_001256946, NM_001256947, NM_001282670, NM_001282671, NM_001282672, NM_001282673, NM_182533

CCDS: CCDS38, CCDS57965, CCDS72686, CCDS72687

Canonical transcript exons

ENST00000378546 — 4 exons

Exon	Start	End
ENSE00001822711	2194688	2194772
ENSE00003467961	2193998	2194133
ENSE00003483048	2189548	2189781
ENSE00003510741	2193639	2193910

Expression profiles

Bgee: expression breadth ubiquitous, 237 present calls, max score 97.46.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 48.8062 / max 298.5511, expressed in 1823 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9873	40.2914	1822
9872	5.2340	1642
9871	2.7249	1368
9874	0.5560	290

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	97.46	gold quality
right uterine tube	UBERON:0001302	96.72	gold quality
endocervix	UBERON:0000458	96.63	gold quality
pituitary gland	UBERON:0000007	96.50	gold quality
apex of heart	UBERON:0002098	96.24	gold quality
right testis	UBERON:0004534	95.94	gold quality
left uterine tube	UBERON:0001303	95.83	gold quality
body of uterus	UBERON:0009853	95.83	gold quality
lower esophagus mucosa	UBERON:0035834	95.78	gold quality
right lobe of thyroid gland	UBERON:0001119	95.71	gold quality
ectocervix	UBERON:0012249	95.67	gold quality
left testis	UBERON:0004533	95.63	gold quality
right adrenal gland	UBERON:0001233	95.61	gold quality
right adrenal gland cortex	UBERON:0035827	95.58	gold quality
metanephros cortex	UBERON:0010533	95.54	gold quality
mucosa of stomach	UBERON:0001199	95.53	gold quality
left lobe of thyroid gland	UBERON:0001120	95.50	gold quality
lower esophagus	UBERON:0013473	95.33	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.33	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.32	gold quality
body of stomach	UBERON:0001161	95.27	gold quality
left adrenal gland cortex	UBERON:0035825	95.27	gold quality
ascending aorta	UBERON:0001496	95.25	gold quality
thoracic aorta	UBERON:0001515	95.23	gold quality
left adrenal gland	UBERON:0001234	95.18	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.08	gold quality
right ovary	UBERON:0002118	95.05	gold quality
left coronary artery	UBERON:0001626	94.78	gold quality
left ovary	UBERON:0002119	94.77	gold quality
hypothalamus	UBERON:0001898	94.73	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.13
E-MTAB-10042	yes	4.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting FAAP20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-5003-5P	99.61	69.13	1624
HSA-MIR-6787-5P	97.54	63.85	457
HSA-MIR-939-5P	97.10	65.80	1579
HSA-MIR-10396B-5P	94.99	63.57	358
HSA-MIR-1908-5P	94.99	63.41	352
HSA-MIR-663A	94.99	63.54	378
HSA-MIR-744-5P	93.78	65.29	230
HSA-MIR-10396A-5P	93.49	65.54	172
HSA-MIR-4508	90.37	59.62	240

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 8)

• FAAP20 contains a conserved ubiquitin-binding zinc-finger domain and binds K-63-linked ubiquitin chains in vitro. The FAAP20-UBZ domain is not required for interaction with FANCA, but is required for DNA-damage-induced chromatin loading of FANCA and the functional integrity of the Fanconi anemia pathway. (PMID:22343915)
• FAAP20 is an important player involved in the Fanconi anemia pathway (PMID:22396592)
• Data indicate that RNF8 and FAAP20 (C1orf86) are needed for efficient Fanconi anemia group D2 protein FANCD2 monoubiquitination. (PMID:22705371)
• FAAP20-ubiquitin interaction expands beyond the compact UBZ domain and requires the folding and interaction of the otherwise disordered C-terminal tail of FAAP20 for high-affinity binding. (PMID:25414354)
• Data suggest Rev1 protein recognition mechanism by Fanconi anemia-associated protein 20 (FAAP20). (PMID:26318859)
• Study identify SCF-FBW7 as a ubiquitin E3 ligase that regulates the cellular FAAP20 levels and Fanconi anemia (FA) pathway. Deregulation of the GSK3beta- and FBW7-dependent FAAP20 degradation leads to a defect in the FA pathway, establishing a direct link between FBW7 and DNA repair. (PMID:27232758)
• Acetylation modulates the Fanconi anemia pathway by protecting FAAP20 from ubiquitin-mediated proteasomal degradation. (PMID:32763975)
• Fanconi anemia associated protein 20 (FAAP20) plays an essential role in homology-directed repair of DNA double-strand breaks. (PMID:37620397)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Faap20	ENSMUSG00000073684
rattus_norvegicus	Faap20	ENSRNOG00000036876

Protein

Protein identifiers

Fanconi anemia core complex-associated protein 20 — Q6NZ36 (reviewed: Q6NZ36)

Alternative names: FANCA-associated protein of 20 kDa, Fanconi anemia-associated protein of 20 kDa

All UniProt accessions (5): Q6NZ36, F6S8H2, H7C2E6, H7C361, H7C3A6

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Fanconi anemia (FA) complex required to recruit the FA complex to DNA interstrand cross-links (ICLs) and promote ICLs repair. Following DNA damage recognizes and binds ‘Lys-63’-linked ubiquitin generated by RNF8 at ICLs and recruits other components of the FA complex. Promotes translesion synthesis via interaction with REV1.

Subunit / interactions. Component of the Fanconi anemia (FA) complex. Interacts with FANCA; interaction is direct. Interacts (via UBZ2-type zinc finger) with REV1; this interaction contributes to the stable association of the two proteins in nuclear foci in response to replication stress. Reported to bind monoubiquitinated REV1; however it binds better to non-ubiquitinated REV1.

Subcellular location. Nucleus. Chromosome.

Domain organisation. The UBZ2-type zinc finger binds both ‘Lys-48’- and ‘Lys-63’-linked polyubiquitin with preference for ‘Lys-63’-linked polyubiquitin.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (6)

UniProt ID	Names	Canonical?
Q6NZ36-1	1	yes
Q6NZ36-2	2
Q6NZ36-3	3
Q6NZ36-4	4
Q6NZ36-5	5
Q6NZ36-6	6

RefSeq proteins (7): NP_001243874, NP_001243875, NP_001243876, NP_001269600, NP_001269601, NP_001269602, NP_872339* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031490	UBZ2_FAAP20	Domain
IPR031491	FANCA_interact	Domain
IPR052689	FA_core_complex_assoc	Family

Pfam: PF15750, PF15751

UniProt features (31 total): splice variant 6, sequence conflict 5, mutagenesis site 4, binding site 4, modified residue 2, region of interest 2, strand 2, chain 1, zinc finger region 1, sequence variant 1, turn 1, helix 1, compositionally biased region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
3WWQ	X-RAY DIFFRACTION	1.9
2MUQ	SOLUTION NMR
2MUR	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NZ36-F1	66.28	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 147; 150; 166; 170

Post-translational modifications (2): 137, 113

Mutagenesis-validated functional residues (4):

Position	Phenotype
147	abolishes binding to ubiquitin. abolishes binding to ubiquitin; when associated with a-150.
150	abolishes binding to ubiquitin; when associated with a-147.
164	abolishes binding to ubiquitin.
170	abolishes binding to ubiquitin.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6783310	Fanconi Anemia Pathway
R-HSA-9833482	PKR-mediated signaling

MSigDB gene sets: 128 (showing top): REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_DNA_DAMAGE_TOLERANCE, MARTINEZ_RB1_TARGETS_DN, GOBP_DNA_DAMAGE_RESPONSE, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_INTERSTRAND_CROSS_LINK_REPAIR, REACTOME_FANCONI_ANEMIA_PATHWAY, DOUGLAS_BMI1_TARGETS_UP, REACTOME_DNA_REPAIR, GOBP_DNA_REPLICATION, GTCGATC_MIR3695P, BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_UP, MULLIGHAN_MLL_SIGNATURE_2_DN, GOCC_FANCONI_ANAEMIA_NUCLEAR_COMPLEX, GOCC_NUCLEAR_BODY

GO Biological Process (4): DNA damage response (GO:0006974), translesion synthesis (GO:0019985), interstrand cross-link repair (GO:0036297), DNA repair (GO:0006281)

GO Molecular Function (7): zinc ion binding (GO:0008270), polyubiquitin modification-dependent protein binding (GO:0031593), ubiquitin binding (GO:0043130), K63-linked polyubiquitin modification-dependent protein binding (GO:0070530), ubiquitin-modified protein reader activity (GO:0140036), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (8): chromatin (GO:0000785), nucleoplasm (GO:0005654), chromosome (GO:0005694), cytosol (GO:0005829), nuclear body (GO:0016604), cell junction (GO:0030054), Fanconi anaemia nuclear complex (GO:0043240), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
DNA Repair	1
Antimicrobial mechanism of IFN-stimulated genes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular membraneless organelle	2
cellular response to stress	1
DNA damage tolerance	1
DNA synthesis involved in DNA replication	1
DNA repair	1
DNA metabolic process	1
DNA damage response	1
transition metal ion binding	1
modification-dependent protein binding	1
ubiquitin-like protein binding	1
polyubiquitin modification-dependent protein binding	1
ubiquitin-like protein reader activity	1
binding	1
cation binding	1
chromosome	1
nuclear lumen	1
cytoplasm	1
nucleoplasm	1
nuclear protein-containing complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

10 interactions, top by confidence:

A	B	Type	Score
REV1	FAAP20	psi-mi:“MI:0407”(direct interaction)	0.540
REV1	FAAP20	psi-mi:“MI:0915”(physical association)	0.540
S100P	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
FAAP20	FANCG	psi-mi:“MI:0914”(association)	0.350
CEP170	ERVK3-1	psi-mi:“MI:2364”(proximity)	0.270
	FAAP20	psi-mi:“MI:0915”(physical association)	0.000
FAAP20		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (124): UBC (Reconstituted Complex), UBC (Co-crystal Structure), UBC (Reconstituted Complex), C1orf86 (Affinity Capture-MS), C1orf86 (Affinity Capture-MS), FANCA (Affinity Capture-MS), C17orf70 (Affinity Capture-MS), FANCB (Affinity Capture-MS), FANCG (Affinity Capture-MS), FANCC (Affinity Capture-MS), FANCE (Affinity Capture-MS), FANCL (Affinity Capture-MS), FANCF (Affinity Capture-MS), FANCA (Co-fractionation), FANCG (Co-fractionation)

ESM2 similar proteins: A0A0U1RRK4, A0A1W2PPE3, A0A1W2PR82, A0A2Z4LIS9, A2VE02, A4D1S0, A5PKC7, A5PL33, A6H7B4, A6NEL2, A6QP24, A6QPM6, A8MTW9, A8MYA2, D3ZAQ5, D4AAA5, E7EW31, O75474, O75638, O89113, O94850, P0C7X2, P14652, P50617, P70339, Q2KIS6, Q3UN58, Q5JPB2, Q5VZ46, Q6GQX2, Q6NZ36, Q6ZSJ8, Q6ZW13, Q76NI1, Q7TNS8, Q80TS7, Q86UU5, Q8IWN7, Q8N6K4, Q8N944

Diamond homologs: A5PKK9, D4AAA5, Q3UN58, Q6NZ36

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
GSK3B	“down-regulates quantity”	FAAP20	phosphorylation

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	17
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1808716	GRCh37/hg19 1p36.33-36.32(chr1:2056695-2447725)x1	Pathogenic
58320	GRCh38/hg38 1p36.33(chr1:2112214-2241243)x1	Pathogenic

SpliceAI

1055 predictions. Top by Δscore:

Variant	Effect	Δscore
1:2193635:TCA:T	donor_loss	0.9800
1:2193636:CA:C	donor_loss	0.9800
1:2193638:C:T	donor_loss	0.9800
1:2193633:ACT:A	donor_loss	0.9700
1:2194001:T:TA	donor_gain	0.9700
1:2194677:C:CA	donor_gain	0.9700
1:2194686:ACCCG:A	donor_gain	0.9700
1:2194687:CCCG:C	donor_gain	0.9700
1:2194687:CCCGC:C	donor_gain	0.9700
1:2194690:G:A	donor_gain	0.9700
1:2191946:G:C	donor_gain	0.9500
1:2194682:CCTCA:C	donor_loss	0.9500
1:2194683:CTCA:C	donor_loss	0.9500
1:2194684:TCAC:T	donor_loss	0.9500
1:2194685:CACCC:C	donor_loss	0.9500
1:2194707:T:TA	donor_gain	0.9500
1:2194719:A:C	donor_gain	0.9500
1:2212396:C:CT	acceptor_gain	0.9500
1:2212396:C:T	acceptor_gain	0.9500
1:2194718:AAC:A	donor_gain	0.9400
1:2193637:A:AC	donor_gain	0.9300
1:2193638:C:CC	donor_gain	0.9300
1:2194681:GCCT:G	donor_loss	0.9300
1:2194717:CA:C	donor_gain	0.9300
1:2194718:AA:A	donor_gain	0.9300
1:2212397:A:T	acceptor_gain	0.9300
1:2191945:A:AC	donor_gain	0.9200
1:2194686:A:AC	donor_gain	0.9200
1:2194686:AC:A	donor_gain	0.9200
1:2194687:C:CC	donor_gain	0.9200

AlphaMissense

1137 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:2193647:G:C	F154L	0.992
1:2193647:G:T	F154L	0.992
1:2193649:A:G	F154L	0.992
1:2193648:A:C	F154C	0.988
1:2193670:A:G	C147R	0.987
1:2193854:A:C	F85L	0.987
1:2193854:A:T	F85L	0.987
1:2193856:A:G	F85L	0.987
1:2189744:A:G	C170R	0.986
1:2193876:A:G	F78S	0.986
1:2193875:G:C	F78L	0.985
1:2193875:G:T	F78L	0.985
1:2193877:A:G	F78L	0.985
1:2189743:C:G	C170S	0.983
1:2189744:A:T	C170S	0.983
1:2189754:G:C	H166Q	0.983
1:2189754:G:T	H166Q	0.983
1:2189740:A:G	L171S	0.981
1:2193660:C:G	C150S	0.980
1:2193661:A:T	C150S	0.980
1:2193850:A:G	W87R	0.980
1:2193850:A:T	W87R	0.980
1:2193661:A:G	C150R	0.979
1:2189742:G:C	C170W	0.978
1:2193648:A:G	F154S	0.978
1:2193669:C:T	C147Y	0.974
1:2193848:C:A	W87C	0.974
1:2193848:C:G	W87C	0.974
1:2189756:G:C	H166D	0.970
1:2193669:C:G	C147S	0.970

dbSNP variants (sampled 300 via entrez): RS1000062211 (1:2198007 C>G,T), RS1000121336 (1:2198283 G>A,T), RS1000153900 (1:2198452 G>A), RS1000440755 (1:2192167 G>A,T), RS1000459521 (1:2197059 G>A), RS1000492189 (1:2197300 C>T), RS1000512883 (1:2201889 C>G), RS1000687465 (1:2212373 G>A,C), RS1000777650 (1:2188143 A>G), RS1000814479 (1:2191235 C>T), RS1000836533 (1:2207626 G>A), RS1000877215 (1:2192391 T>C), RS1000939109 (1:2191901 T>C), RS1000978110 (1:2212336 C>A,G), RS1001020011 (1:2205102 T>A,C,G)

Disease associations

OMIM: gene MIM:615183 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

92 associations (top):

Study	Trait	p-value
GCST005951_34	Body mass index	3.000000e-08
GCST005951_35	Body mass index	4.000000e-08
GCST006913_5	Sedentary behaviour duration	5.000000e-08
GCST010346_12	TPE interval (resting)	4.000000e-10
GCST010796_2431	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2432	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_2433	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_2434	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_2435	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2436	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_2437	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-09
GCST010796_2438	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-10
GCST010796_2439	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-10
GCST010796_2440	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-10
GCST010796_2441	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-11
GCST010796_2442	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-11
GCST010796_2443	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-10
GCST010796_2444	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2445	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2446	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2447	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_2448	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_2449	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-11
GCST010796_2450	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-12
GCST010796_2451	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-13
GCST010796_2452	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-15
GCST010796_2453	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-16
GCST010796_2454	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-17
GCST010796_2455	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-17
GCST010796_2456	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-17

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008002	physical activity measurement
EFO:0004644	TPE interval measurement
EFO:0004327	electrocardiography

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects methylation, increases abundance, affects expression	2
Particulate Matter	increases expression, decreases expression, decreases reaction, affects cotreatment, increases abundance	2
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
K 7174	decreases expression	1
ICG 001	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
(+)-JQ1 compound	decreases expression	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Arsenic	affects methylation	1
Atrazine	decreases expression	1
Vehicle Emissions	decreases expression, decreases reaction	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Diazinon	increases methylation	1
Formaldehyde	decreases expression	1
Gasoline	increases abundance, increases expression, affects cotreatment	1
Methapyrilene	decreases methylation	1
Nitrogen Dioxide	increases abundance, affects methylation	1
Ozone	affects expression, increases abundance	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Valproic Acid	increases methylation	1
Gold Compounds	increases expression	1
Cadmium Chloride	increases expression	1
1-Butanol	affects cotreatment, increases abundance, increases expression	1
Permethrin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.